Novel ways to sensitise gastrointestinal cancer to apoptosis

Gut

Volumn 58, Issue 7, 2009, Pages 1010-1024

  Schulze Bergkamen, H ^a   Weinmann, A ^a   Moehler, M ^a   Siebler, J ^a   Galle, P R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 263; AMG 655; AMG 951; APC 2996; APOMAB; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CS 1008; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GOSSYPOL; IMATINIB; IRINOTECAN; ISOSORBIDE; LBY 135; LEXATUMUMAB; MAPATUMUMAB; MICRORNA; OBATOCLAX; OBLIMERSEN; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SORAFENIB; SPC 2996; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; CANCER GENE THERAPY; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG TARGETING; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE SILENCING; HUMAN; LIVER CELL CARCINOMA; ONCOLYTIC VIROTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; SUICIDE GENE THERAPY; TRANSCRIPTION TERMINATION;

APOPTOSIS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 67649656258     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.164350     Document Type: Review

References (113)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257
2. Peter ME, Scaffidi C, Medema JP, et al. The death receptors. Results Prob Cell Differ 1999;23:25-63.
3. Tartaglia LA, Ayres TM, Wong GH, et al. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993;74:845-853 (Pubitemid 23270604)
4. Vandenabeele P, Declercq W, Vanhaesebroeck B, et al. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol 1995;154:2904-2913
5. Hsu H, Shu HB, Pan MG, et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299-308. (Pubitemid 26042835)
6. Manna SK, Mukhopadhyay A, Aggarwal BB. IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol 2000;165:4927-4934 (Pubitemid 30809417)
7. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305 (Pubitemid 19196649)
8. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a deathinducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-5588
9. Walczak H, Sprick MR. Biochemistry and function of the DISC. Trends Biochem Sci 2001;26:452-453 (Pubitemid 32607488)
10. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-430 (Pubitemid 37328939)
11. Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000;103:839-842
12. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
13. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006;7:988-994 (Pubitemid 44480512)
14. Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009;16:3-11.
15. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237 (Pubitemid 40314954)
16. Schulze-Bergkamen H, Schuchmann M, Fleischer B, et al. The role of apoptosis versus oncotic necrosis in liver injury: facts or faith? J Hepatol 2006;44:984-993
17. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol 2002;3:672-683 (Pubitemid 35314910)
18. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007;120:781-787 (Pubitemid 46175397)
19. Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract 2007;4:245-255 (Pubitemid 46510534)
20. Hussain S, Pluckthun A, Allen TM, et al. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 2007;6:3019-3027 (Pubitemid 350206780)
21. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
22. Cattaneo R, Miest T, Shashkova EV, et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6:529-540 (Pubitemid 351850977)
23. Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009;17:389-394
24. Liu T, Park B, Hwang T, et al. Clinical proof-of-concept with JX-594, a novel targeted multi-mechanistic oncolytic poxvirus, in patients with refractory liver tumors. J Clin Oncol 2008;26:abstr 3573.
25. Sieben M, Herzer K, Zeidler M, et al. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol 2008;14:3819-3828
26. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498 (Pubitemid 32494397)
27. Li SD, Huang L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 2008;9:1317-1323
28. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2008. Epub ahead of print.
29. Majoros IJ, Williams CR, Baker JR Jr. Current dendrimer applications in cancer diagnosis and therapy. Curr Top Med Chem 2008;8:1165-1179
30. Oliver JC, Yen Y, Synold TW, et al. A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. J Clin Oncol 2008;26:abstr 14538.
31. Huang RC, Chang CC, Mold D. Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol 2006;33:479-485 (Pubitemid 44142741)
32. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2008. Epub ahead of print
33. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting. J Hematol Oncol 2008;1:20.
34. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
35. Lee SH, Shin MS, Lee HS, et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001;32:250-256 (Pubitemid 32246797)
36. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 1996;2:1361-1366
37. Strand S, Vollmer P, van den Abeelen L, et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004;23:3732-3736 (Pubitemid 38658442)
38. Ullenhag GJ, Mukherjee A, Watson NF, et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007;13:5070-5075 (Pubitemid 47502072)
39. Herrmann T, Grosse-Hovest L, Otz T, et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008;68:1221-1227 (Pubitemid 351272242)
40. Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006;6:6. (Pubitemid 43853924)
41. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601. (Pubitemid 41095061)
42. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-798
43. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008;9:1002-1011
44. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3450-3455
45. Sikic BI, Wakelee H, Von Mehren M, et al. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol 2007;25:abstr 14006.
46. Camidge D, Herbst RS, Gordon M, et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol 2007;25:abstr 3582.
47. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apopoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 2007;25:abstr 3534.
48. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008;263:14-25.
49. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-1077 (Pubitemid 47517508)
50. Koschny R, Walczak H, Ganten TM. The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-935 (Pubitemid 47282789)
51. Schuchmann M, Schulze-Bergkamen H, Fleischer B, et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006;15:227-230
52. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targ 2008;8:37-46. (Pubitemid 351237908)
53. Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL - secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-9623
54. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009;218:13-21.
55. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94. (Pubitemid 38281265)
56. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, et al. Bcl-x(L) and myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol 2008;14:3829-3840
57. Wright CW, Duckett CS. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 2005;115:2673-2678 (Pubitemid 41434391)
58. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471-1474 (Pubitemid 39167668)
59. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
60. Idenoue S, Hirohashi Y, Torigoe T, et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005;11:1474-1482 (Pubitemid 40315229)
61. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003;100:13791-13796 (Pubitemid 37499145)
62. Graff JR, Konicek BW, Carter JH, et al. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008;68:631-634 (Pubitemid 351206735)
63. Tamm I. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer. Curr Opin Investig Drugs 2008;9:638-646 (Pubitemid 351777167)
64. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225
65. Drescher D, Moehler M, Gockel I, et al. Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma - a rationale for a molecular targeting strategy? World J Gastroenterol 2007;13:3605-3609
66. Hara F, Aoe M, Doihara H, et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005;226:37-47. (Pubitemid 40943428)
67. Cunningham C, Wong RP, D'haens G, et al. A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. J Clin Oncol 2008;26:abstr 4028.
68. Moehler M, Frings C, Mueller A, et al. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol 2008;14:4156-4167
69. Liu X, Yao W, Newton RC, et al. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011.
70. Rodon J, DeSantos V, Ferry RJ Jr, et al. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-2588
71. Massague J. TGFbeta in cancer. Cell 2008;134:215-230
72. Schlingensiepen KH, Fischer-Blass B, Schmaus S, et al. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008;177:137-150
73. Michael M, Vlahovic G, Khamly K, et al. Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel (Doc) with or without AG-013736, a VEGF inhibitor. J Clin Oncol 2008;26:abstr 3549.
74. Garrett CR, Siu LL, El-Khoueiry AB, et al. A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy. J Clin Oncol 2008;26:abstr 4111.
75. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274 (Pubitemid 46962095)
76. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68:1953-1961
77. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995
78. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27:5477-5485
79. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-1983
80. Strimpakos AS, Karapanagiotou EM, Saif WM, et al. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009;35:148-159
81. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241 (Pubitemid 27456390)
82. Patra SK, Szyf M. DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A. FEBS J 2008;275:5217-5235
83. Dritschilo A, Huang CH, Rudin CM, et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006;12:1251-1259 (Pubitemid 43342516)
84. Cox AD, Der CJ. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2002;2:388-393
85. Rosen LS, Galatin P, Fehling JM, et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. J Clin Oncol 2008;26:abstr 14585.
86. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 2007;13:5665-5669 (Pubitemid 47583890)
87. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683 (Pubitemid 26130197)
88. Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006;5:2251-2260 (Pubitemid 44530462)
89. Resta LP, Ermisch S, Collins C, et al. Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer. J Clin Oncol 2008;26:abstr 3529.
90. Sarno S, Pinna LA. Protein kinase CK2 as a druggable target. Mol Biosyst 2008;4:889-894
91. Kloth MT, Laughlin KK, Biscardi JS, et al. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 2003;278:1671-1679 (Pubitemid 36801399)
92. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-4988 (Pubitemid 46910207)
93. Koschny R, Ganten TM, Sykora J, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007;45:649-658 (Pubitemid 46450616)
94. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 (Pubitemid 27131374)
95. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-622 (Pubitemid 30078542)
96. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008;7:1031-1040
97. Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs 2008;17:1865-1882
98. Muller M, Schleithoff ES, Stremmel W, et al. One, two, three - p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006;9:288-306.
99. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-5772 (Pubitemid 30808313)
100. Kern MA, Haugg AM, Koch AF, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006;66:7059-7066 (Pubitemid 44197682)
101. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408-9421 (Pubitemid 46260200)
102. Sharma PS, Sharma R, Tyagi R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 2008;8:53-75. (Pubitemid 351237910)
103. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-3845 (Pubitemid 40685604)
104. Robert F, Hurwitz H, Verschraegen C, et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. J Clin Oncol 2008;26:abstr 14642.
105. Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 2001;98:392-394 (Pubitemid 32105049)
106. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-149 (Pubitemid 34887610)
107. Dario LS, Rosa MA, Mariela E, et al. Chromatin remodeling agents for cancer therapy. Rev Recent Clin Trials 2008;3:192-203.
108. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008;3:28-37. (Pubitemid 351540961)
109. Kim YH, Park JW, Lee JY, et al. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004;25:1813-1820 (Pubitemid 39405899)
110. Bordonaro M, Lazarova DL, Sartorelli AC. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer? Oncol Res 2008;17:1-9.
111. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nature Med 2006;12:410-416
112. Blankenberg FG. In vivo imaging of apoptosis. Cancer Biol Ther 2008;7:1525-1532
113. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008;34:737-749